In a regulatory filing, Eli Lilly (LLY) CEO David Ricks disclosed the purchase of 1,632 common shares of the company on August 12 at a price of $644.769 per share, or a total consideration of $1.05M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Texas Sues Eli Lilly (LLY) for Allegedly Bribing Doctors to Prescribe Its Drugs
- Eli Lilly sued by Texas AG, company accused of ‘bribing providers’
- Eli Lilly’s Orforglipron Study: A Potential Game-Changer in Obesity Treatment
- Eli Lilly’s Orforglipron Study: A New Hope for Obesity Treatment?
- VOO ETF News, 8/12/2025